Small molecule-mediated refolding and activation of myosin motor function

eLife

Volumn 2014, Issue 3, 2014, Pages

  Radke, Michael B ^a   Taft, Manuel H ^a   Stapel, Britta ^a   Hilfiker Kleiner, Denise ^a   Preller, Matthias ^a,b   Manstein, Dietmar J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b DESY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 [1 (3, 4 DIMETHOXYBENZOYL) 1, 2, 3, 4 TETRAHYDRO 6 QUINOLYL] 3, 6 DIHYDRO 6 METHYL 2H 1, 3, 4 THIADIAZIN 2 ONE; ADENOSINE TRIPHOSPHATASE; MYOSIN; UNCLASSIFIED DRUG; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ACTIN; ADENOSINE TRIPHOSPHATE; CARDIAC MYOSIN; CARDIOTONIC AGENT; ENZYME ACTIVATOR; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN; THIADIAZINE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CELL CULTURE; CIRCULAR DICHROISM; CONTROLLED STUDY; DENATURATION; DRUG DISTRIBUTION; HEART MUSCLE CELL; HEAT STRESS; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIGHT SCATTERING; MOLECULAR MODEL; MOTOR PERFORMANCE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN REFOLDING; RAT; REAL TIME POLYMERASE CHAIN REACTION; TEMPERATURE; ANIMAL; BINDING SITE; CHEMISTRY; DICTYOSTELIUM; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETICS; HEART CONTRACTION; HUMAN; HYDROLYSIS; KINETICS; METABOLISM; MOLECULAR DOCKING; NEWBORN; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ACTINS; ADENOSINE TRIPHOSPHATE; ALLOSTERIC REGULATION; ANIMALS; ANIMALS, NEWBORN; BINDING SITES; CARDIAC MYOSINS; CARDIOTONIC AGENTS; CATALYTIC DOMAIN; CELLS, CULTURED; DICTYOSTELIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; HYDROLYSIS; KINETICS; MOLECULAR DOCKING SIMULATION; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROTEIN CONFORMATION; PROTEIN REFOLDING; QUINOLINES; RATS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZINES;

EID: 84898731649     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.01603     Document Type: Article

References (54)

1. Aggeli I-KS, Gaitanaki C, Lazou A, Beis I. 2002. Alpha(1)-and beta-adrenoceptor stimulation differentially activate p38-MAPK and atrial natriuretic peptide production in the perfused amphibian heart. The Journal of Experimental Biology 205:2387-2397.
2. Allen DL, Harrison BC, Maass A, Bell ML, Byrnes WC, Leinwand LA. 2001. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. Journal of Applied Physiology 90:1900-1908.
3. Amrute-Nayak M, Diensthuber RP, Steffen W, Kathmann D, Hartmann FK, Fedorov R, Urbanke C, Manstein DJ, Brenner B, Tsiavaliaris G. 2010. Targeted optimization of a protein nanomachine for operation in biohybrid devices. Angewandte Chemie 49:312-316. doi: 10.1002/anie.200905200.
4. Anfinsen CB, Scheraga HA. 1975. Experimental and theoretical aspects of protein folding. Advances in Protein Chemistry 29:205-300. doi: 10.1016/S0065-3233(08)60413-1.
5. Anson M, Geeves MA, Kurzawa SE, Manstein DJ. 1996. Myosin motors with artificial lever arms. EMBO Journal 15:6069-6074.
6. Baldwin KM, Haddad F. 2001. Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. Journal of Applied Physiology 90:345-357.
7. Bartlett AI, Radford SE. 2009. An expanding arsenal of experimental methods yields an explosion of insights into protein folding mechanisms. Nature Structural & Molecular Biology 16:582-588. doi: 10.1038/nsmb.1592.
8. Batra R, Manstein DJ. 1999. Functional characterisation of Dictyostelium myosin II with conserved tryptophanyl residue 501 mutated to tyrosine. Biological Chemistry 380:1017-1023. doi: 10.1515/BC.1999.126.
9. Beier N, Harting J, Jonas R, Klockow M, Lues I, Haeusler G. 1991. The novel cardiotonic agent EMD 53 998 is a potent "calcium sensitizer". Journal of Cardiovascular Pharmacology 18:17-27. doi: 10.1097/00005344-199107000-00004.
10. Brune M, Hunter JL, Corrie JE, Webb MR. 1994. Direct, real-time measurement of rapid inorganic phosphate release using a novel fluorescent probe and its application to actomyosin subfragment 1 ATPase. Biochemistry 33:8262-8271. doi: 10.1021/bi00193a013.
11. Chen J-H, Michiue T, Ishikawa T, Maeda H. 2012. Molecular pathology of natriuretic peptides in the myocardium with special regard to fatal intoxication, hypothermia, and hyperthermia. International Journal of Legal Medicine 126:747-756. doi: 10.1007/s00414-012-0732-4.
12. Deacon JC, Bloemink MJ, Rezavandi H, Geeves MA, Leinwand LA. 2012. Identification of functional differences between recombinant human α and β cardiac myosin motors. Cellular and Molecular Life Sciences 69:2261-2277. doi: 10.1007/s00018-012-0927-3.
13. Duhr S, Braun D. 2006. Why molecules move along a temperature gradient. Proceedings of the National Academy of Sciences of the United States of America 103:19678-19682. doi: 10.1073/pnas.0603873103.
14. Ferroni C, Hano O, Ventura C, Lakatta EG, Klockow M, Spurgeon H, Capogrossi MC. 1991. A novel positive inotropic substance enhances contractility without increasing the Ca2+ transient in rat myocardium. Journal of Molecular and Cellular Cardiology 23:325-331. doi: 10.1016/0022-2828(91)90068-W.
15. Fujita-Becker S, Dürrwang U, Erent M, Clark RJ, Geeves MA, Manstein DJ. 2005. Changes in Mg2+ ion concentration and heavy chain phosphorylation regulate the motor activity of a class I myosin. The Journal of Biological Chemistry 280:6064-6071. doi: 10.1074/jbc.M412473200.
16. Fujita-Becker S, Tsiavaliaris G, Ohkura R, Shimada T, Manstein DJ, Sutoh K. 2006. Functional characterization of the N-terminal region of myosin-2. The Journal of Biological Chemistry 281:36102-36109. doi: 10.1074/jbc.M605171200.
17. Furch M, Geeves MA, Manstein DJ. 1998. Modulation of actin affinity and actomyosin adenosine triphosphatase by charge changes in the myosin motor domain. Biochemistry 37:6317-6326. doi: 10.1021/bi972851y.
18. Gambassi G, Capogrossi MC, Klockow M, Lakatta EG. 1993. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes. The American Journal of Physiology 264:H728-H738.
19. Getty AL, Pearce DA. 2011. Interactions of the proteins of neuronal ceroid lipofuscinosis: clues to function. Cellular and Molecular Life Sciences 68:453-474. doi: 10.1007/s00018-010-0468-6.
20. Getty AL, Benedict JW, Pearce DA. 2011. A novel interaction of CLN3 with nonmuscle myosin-IIB and defects in cell motility of Cln3(-/-) cells. Experimental Cell Research 317:51-69. doi: 10.1016/j.yexcr.2010.09.007.
21. Greenberg MJ, Moore JR. 2010. The molecular basis of frictional loads in the in vitro motility assay with applications to the study of the loaded mechanochemistry of molecular motors. Cytoskeleton (Hoboken) 67:273-285. doi: 10.1002/cm.20441.
22. Hartl FU, Bracher A, Hayer-Hartl M. 2011. Molecular chaperones in protein folding and proteostasis. Nature 475:324-332. doi: 10.1038/nature10317.
23. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B, Hillmer A, Schmiedl A, Ding Z, Podewski E, Podewski E, Poli V, Schneider MD, Schulz R, Park JK, Wollert KC, Drexler H. 2004. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circulation Research 95:187-195. doi: 10.1161/01.RES.0000134921.50377.61.
24. Hilfiker-Kleiner D, Hilfiker A, Castellazzi M, Wollert KC, Trautwein C, Schunkert H, Drexler H. 2006. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity. Cardiovascular Research 71:108-117. doi: 10.1016/j.cardiores.2006.02.032.
25. Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H. 2010. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 122:145-155. doi: 10.1161/CIRCULATIONAHA.109.933127.
26. Hoch M, Fischer P, Stapel B, Missol-Kolka E, Sekkali B, Scherr M, Favret F, Braun T, Eder M, Schuster-Gossler K, Gossler A, Hilfiker A, Balligand JL, Drexler H, Hilfiker-Kleiner D. 2011. Erythropoietin preserves the endothelial differentiation capacity of cardiac progenitor cells and reduces heart failure during anticancer therapies. Cell Stem Cell 9:131-143. doi: 10.1016/j.stem.2011.07.
27. Jacques AM, Briceno N, Messer AE, Gallon CE, Jalilzadeh S, Garcia E, Kikonda-Kanda G, Goddard J, Harding SE, Watkins H, Esteban MT, Tsang VT, McKenna WJ, Marston SB. 2008. The molecular phenotype of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovascular Research 79:481-491. doi: 10.1093/cvr/cvn094.
28. Kraft T, Brenner B. 1997. Force enhancement without changes in cross-bridge turnover kinetics: the effect of EMD 57033. Biophysical Journal 72:272-281. doi: 10.1016/S0006-3495(97)78666-1.
29. Lard M, Ten Siethoff L, Kumar S, Persson M, Te Kronnie G, Linke H, Månsson A. 2013. Ultrafast molecular motor driven nanoseparation and biosensing. Biosensors & Bioelectronics 48:145-152. doi: 10.1016/j.bios.2013.03.071.
30. Lehrer SS, Kerwar G. 1972. Intrinsic fluorescence of actin. Biochemistry 11:1211-1217. doi: 10.1021/bi00757a015.
31. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. 2011. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 331:1439-1443. doi: 10.1126/science.1200113.
32. Manstein DJ, Hunt DM. 1995. Overexpression of myosin motor domains in Dictyostelium: screening of transformants and purification of the affinity tagged protein. Journal of Muscle Research Cell Motility 16:325-332. doi: 10.1007/BF00121141.
33. Margossian SS, Lowey S. 1982. Preparation of myosin and its subfragments from rabbit skeletal muscle. Methods in Enzymology 85:55-71.
34. Marijon E, Mirabel M, Celermajer DS, Jouven X. 2012. Rheumatic heart disease. Lancet 379:953-964. doi: 10.1016/S0140-6736(11)61171-9.
35. Mercadier JJ, Bouveret P, Gorza L, Schiaffino S, Clark WA, Zak R, Swynghedauw B, Schwartz K. 1983. Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circulation Research 53:52-62. doi: 10.1161/01.RES.53.1.52.
36. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry 19:1639-1662. doi: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.
37. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30:2785-2791. doi: 10.1002/jcc.21256.
38. Nalepa G, Rolfe M, Harper JW. 2006. Drug discovery in the ubiquitin-proteasome system. Nature Reviews Drug Discovery 5:596-613. doi: 10.1038/nrd2056.
39. Ogawa Y, Itoh H, Nakao K. 1995. Molecular biology and biochemistry of natriuretic peptide family. Clinical and Experimental Pharmacology and Physiology 22:49-53. doi: 10.1111/j.1440-1681.1995.tb01918.x.
40. Oldfors A. 2007. Hereditary myosin myopathies. Neuromuscular Disorders 17:355-367. doi: 10.1016/j.nmd.2007.02.008.
41. Pant K, Watt J, Greenberg M, Jones M, Szczesna-Cordary D, Moore JR. 2009. Removal of the cardiac myosin regulatory light chain increases isometric force production. FASEB Journal 23:3571-3580. doi: 10.1096/fj.08-126672.
42. Persson M, Gullberg M, Tolf C, Lindberg AM, Månsson A, Kocer A. 2013. Transportation of nanoscale cargoes by myosin propelled actin filaments. PLOS ONE 8:e55931. doi: 10.1371/journal.pone.0055931.
43. Ponomarev MA, Furch M, Levitsky DI, Manstein DJ. 2000. Charge changes in loop 2 affect the thermal unfolding of the myosin motor domain bound to F-actin. Biochemistry 39:4527-4532. doi: 10.1021/bi992420a.
44. Sali A, Blundell TL. 1993. Comparative protein modelling by satisfaction of spatial restraints. Journal of Molecular Biology 234:779-815. doi: 10.1006/jmbi.1993.1626.
45. Sanner MF. 1999. Python: a programming language for software integration and development. Journal of Molecular Graphics & Modelling 17:57-61.
46. Senisterra GA, Markin E, Yamazaki K, Hui R, Vedadi M, Awrey DE. 2006. Screening for ligands using a generic and high-throughput light-scattering-based assay. Journal of Biomolecular Screening 11:940-948. doi: 10.1177/1087057106294699.
47. Senzaki H, Isoda T, Paolocci N, Ekelund U, Hare JM, Kass DA. 2000. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033. Circulation 101:1040-1048. doi: 10.1161/01.CIR.101.9.1040.
48. Solaro RJ, Gambassi G, Warshaw DM, Keller MR, Spurgeon HA, Beier N, Lakatta EG. 1993. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments. Circulation Research 73:981-990. doi: 10.1161/01.RES.73.6.981.
49. Taft MH, Hartmann FK, Rump A, Keller H, Chizhov I, Manstein DJ, Tsiavaliaris G. 2008. Dictyostelium myosin-5b is a conditional processive motor. The Journal of Biological Chemistry 283:26902-26910. doi: 10.1074/jbc.M802957200.
50. Tsiavaliaris G, Fujita-Becker S, Batra R, Levitsky DI, Kull FJ, Geeves MA, Manstein DJ. 2002. Mutations in the relay loop region result in dominant-negative inhibition of myosin II function in Dictyostelium. EMBO Reports 3:1099-1105. doi: 10.1093/embo-reports/kvf214.
51. Tyedmers J, Mogk A, Bukau B. 2010. Cellular strategies for controlling protein aggregation. Nature Reviews Molecular Cell Biology 11:777-788. doi: 10.1038/nrm2993.
52. Walsh R, Rutland C, Thomas R, Loughna S. 2010. Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations. Cardiology 115:49-60. doi: 10.1159/000252808.
53. Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S. 2010. Protein-binding assays in biological liquids using microscale thermophoresis. Nature Communications 1:100. doi: 10.1038/ncomms1093.
54. Willis MS, Patterson C. 2013. Proteotoxicity and cardiac dysfunction-Alzheimer's disease of the heart? The New England Journal of Medicine 368:455-464. doi: 10.1056/NEJMra1106180.